Form 8-K - Current report:
SEC Accession No. 0001193125-23-046525
Filing Date
2023-02-23
Accepted
2023-02-23 16:07:08
Documents
12
Period of Report
2023-02-17
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d463670d8k.htm   iXBRL 8-K 25585
  Complete submission text file 0001193125-23-046525.txt   143746

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA plrx-20230217.xsd EX-101.SCH 2853
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE plrx-20230217_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE plrx-20230217_pre.xml EX-101.PRE 10814
6 EXTRACTED XBRL INSTANCE DOCUMENT d463670d8k_htm.xml XML 3245
Mailing Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 650-481-6770
PLIANT THERAPEUTICS, INC. (Filer) CIK: 0001746473 (see all company filings)

EIN.: 474272481 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39303 | Film No.: 23659640
SIC: 2834 Pharmaceutical Preparations